Tonya J Webb

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) comprising approximately 85% of cases. In addition to chemotherapy, targeted treatments including epidermal growth factor receptor inhibitors (EGFRi), have emerged as an additional therapeutic strategy. However, patients frequently develop resistance to these therapies.

Abstract Minority groups face barriers in accessing quality health care, professional advancement, and representation in immunology research efforts as a result of institutional racism that if unaddressed can perpetuate a lack of diversity.

The role of ILCs in colorectal cancer The presence of ILCs has been detected in multiple types of cancer (188), and evidence for both anti- and pro-tumorigenic roles has been described for all helper ILCs. The conflicting evidence may be explained by their heterogeneity in terms of function, ontogeny, and location combined with differences in cancer microenvironment (189) ILC1s, secreting abundant IFN-γ and TNF-α, are a recognized driver of chronic intestinal inflammation, and they may thus...